Option chain shows key data for Context Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Context Therapeutics.

Context Therapeutics (NASDAQ:CNTX) Stock, Option Chain

Context Therapeutics

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

News

Initiation

Pre-Market Outlook

Analyst Ratings

Trading Ideas

CNTX

LEVI

NKTR

SMMT

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

AADI

ALRN

ATAK

ATNI

BATL

BRLI

BRSH

CHSN

CING

ELAB

EOSE

FRGT

GETR

GNLX

HSCS

ICCT

INDV

INHD

LRHC

MGRX

Nuveen Insured California Premium Fund Ii

NCPL

NCSM

NYMT

SCHL

SLGC

VRCA

VRPX

Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter financial results.

Quanex Building Products shares fell 10.7% to $30.95 on Friday.

Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

ALEC

BCYC

KIND

MNSO

U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Friday.

Here are some other big stocks recording gains in today’s session.

Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday

Context Therapeutics Inc

Opinion

Press Releases

Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

Management

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

Context Therapeutics to Participate in Upcoming Investor Conferences

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Earnings

Context Therapeutics Reports Full Year 2024 Operating and Financial Results

Health Care

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

ALLO

ERAS

ONCY

RXRX

TSX:ONC

ALT5 Sigma

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

Assertio Holdings

Biote

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Ikena Oncology

Opus Genetics

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

Nektar Therapeutics

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

NeOnc Technologies Holdings, Inc. - Common Stock

NeOnc Technologies

Nutriband

OptiNose

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Cassava Sciences

scPharmaceuticals

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Veru

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

Ventyx Biosciences

D. Boral Capital

HC Wainwright & Co.

JMP Securities

Piper Sandler

Maxim Group

Comments

Context Therapeutics

Context Therapeutics (CNTX) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell